Among the SVZM+ exclusive mutations identified in the TCGA cohort, the ephrin family member EPHA1 mutation may provide an interesting therapeutic target as it was recently attributed to an improved response to anti-PD-L1 immune checkpoint inhibition in lung cancer [11]. The gene discussed is EPHA1; the disease is lung carcinoma.